First Clinical Data for X4P-001-RD Demonstrating Preliminary Activity in Patients with WHIM Syndrome will be Presented at American Society for Hematology Annual Meeting

X4 Pharmaceuticals, a clinical stage biotechnology company developing novel CXCR4 inhibitor drugs to improve immune cell trafficking to treat cancer and rare disease, today announced that Dr. David C. Dale, MD will present the first clinical data from an ongoing study of X4P-001-RD in patients with WHIM Syndrome, a sub-type of a primary immunodeficiency disease, at the 59th Annual Meeting of the American Society for Hematology (ASH). Preliminary data from these abstracts are available on the ASH conference website. The details of the poster presentation is as follows:

X4P-001: A Novel Molecularly-Targeted Oral Therapy for WHIM Syndrome
Saturday, December 9, 2017, Abstract # 995, Presenter: David C. Dale, MD

“We are very pleased to share preliminary data showing that X4P-001-RD has a meaningful impact on the levels of circulating white blood cells in this severely immunodeficient patient population,” said Paula Ragan, PhD, President and CEO of X4. “These data demonstrate the potential of X4P-001-RD to benefit patients with WHIM who otherwise have no approved treatment options and support our goal of advancing toward a pivotal study.”

This entry was posted in Recent Development News: Q4 - 2017, Recent Developments. Bookmark the permalink.
Read Full Article »